Personalised therapy for multiple sclerosis

Project Details

At the present time, no neuroregenerative or remyelinating therapies are available for clinical use and so the core of multiple sclerosis management lies in preventing clinical relapses and relapse-related disability accrual.

Despite the rapid development of pharmacotherapy, prevention of disability in patients with multiple sclerosis has been suboptimal. The most effective of the available immunotherapies mitigate the short-term risk of disability progression by 30-42%. This imperfect result is mainly attributed to the large inter-individual variability in the multiple sclerosis phenotype and treatment response. From the patients’ perspective, any time spent on disease modifying therapies with suboptimal individual effect translates into ongoing loss of capacity. While an enormous effort is being invested into developing new, more potent therapies, it is of paramount importance that use of the currently available therapies is optimised.

Researchers

  • A/Prof Tomas Kalincik, Project leader
  • Dr Amy Kunchok, Research fellow
  • Mr Adam Fambiatos, MD student

Collaborators

  • The MSBase collaboration
  • Teams at Karolinska Institute (Stockholm)
  • University Hospital Vall d'Hebron (Spain)

Funding

  • NHMRC project grant 1083539, Treating progressive MS
  • University of Melbourne
  • Biogen Fellowship in MS Registries Research

Research Publications

  1. Signori A, Izquierdo G, Lugaresi A, Hupperts R, Grand'Maison F, Sola P, et al. on behalf of the MSBase Study Group (in press) Long-term disability trajectories in primary progressive MS in patients - a latent class growth analysis. Mult Scler, accepted 18/03/2017
  2. Jokubaitis V, Spelman T, Kalincik T, Lorscheider  J, Havrdova E, Horakova D, et al., on behalf of the MSBase Study Group (2016) Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol 80(1):89-100
  3. Uher T, Vaneckova M, Sobisek L,... Kalincik T* and Horakova D* (2017). Combining clinical and MRI predictors enhances prediction of 12-year disability in multiple sclerosis. Mult Scler 23(1):51-61
  4. Uher T, Horakova D, Kalincik T, Bergsland N, Tyblova M, Ramasamy D, et al. (2015) Early MRI predictors of clinical progression over 48 months in patients with clinically isolated syndrome treated with intramuscular interferon β1a. Eur J Neurol 22(7):1113-1123
  5. Jokubaitis VG, Spelman T, Kalincik T, Izquierdo G, Grand’Maison F, Duquette P et al., on behalf of the MSBase Study Group (2015) Predictors of disability worsening in clinically isolated syndrome. Ann Clin Transl Neurol 2(5):479-91
  6. Horakova D, Kalincik T, Dolezal O, Krasensky J, Vaneckova M, Seidl Z, Havrdova E (2012) Early predictors of non-response to interferon in multiple sclerosis. Acta Neurol Scand 126(6):390-7

Research Group

CORe Unit (Clinical Outcomes Research Unit)



Faculty Research Themes

Neuroscience



Key Contact

For further information about this research, please contact the research group leader.

Department / Centre

Medicine and Radiology

Unit / Centre

CORe Unit (Clinical Outcomes Research Unit)